TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Auriculotherapy Effectiveness on Stress and Anxiety in Nursing Student

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Average and high score by the List of Stress Symptoms~* Voluntary participation in the study~* Availability of time for submission to the sessions~Exclusion Criteria:~* Pregnancy~* Medical license or vacation during the period~* Low score of stress

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Auriculotherapy Group (Type: ACTIVE_COMPARATOR): The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Two points were chosen to treat stress and anxiety (Shenmen and Brainstem).
- Placebo Group (Type: PLACEBO_COMPARATOR): Auriculotherapy by sham, at the fist and outer ear points. These points aren't indicated for stress and anxiety.
- Control Group (Type: NO_INTERVENTION): Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 40 to 85 years with a clinical diagnosis of OA of the target knee according to the American College of Rheumatology (ACR) criteria, including:~* Symptoms for at least 6 months prior to screening, AND~* Knee pain in the target knee for 30 days of the preceding month (periarticular knee pain due to OA and not due to other conditions such as bursitis, tendonitis, etc.) AND~* The pain in the target knee required the use of nonsteroidal anti-inflammatory drugs (NSAIDs) either over the counter (OTC) per recommendation of a physician or prescribed.~Exclusion Criteria:~* Body mass index (BMI) \> 40~* Any subject who disobeyed the restriction of prohibited therapies (i.e., use rescue medication) during Screening Washout Period.~* Secondary OA of the knee (rheumatoid arthritis, gout, psoriasis, syphilitic neuropathy, ochronosis, metabolic or other primary bone disease or acute trauma).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac Sodium Active Topical Patch 1 (Type: EXPERIMENTAL): Diclofenac sodium 1 topical patches will be compared against placebo patches.
- Diclofenac Sodium Active Topical Patch 2 (Type: EXPERIMENTAL): Diclofenac sodium 2 topical patches will be compared against placebo patches.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed newly diagnosed primary CNS lymphoma confirmed by 1 of the following methods:~  * Brain biopsy or resection~ * Cerebrospinal fluid (CSF) cytology~    * Positive CSF cytology with or without measurable intracranial disease~* No evidence of systemic non-Hodgkin's lymphoma~  * CT scan or MRI of the chest, abdomen, and pelvis AND bilateral bone marrow biopsy or unilateral biopsy with a 2cm core biopsy specimen that is negative for extracerebral source of lymphoma~* Measurable contrast-enhancing disease by MRI of the brain and spine (plus gadolinium) unless CSF cytology positive~* No evidence of pleural effusions or ascites~PATIENT CHARACTERISTICS:~Age~* Any age~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~Hepatic~* ALT and AST ≤ 2 times upper limit of normal~* Bilirubin ≤ 2 mg/dL~Renal~* Creatinine clearance ≥ 50 mL/min~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 6 months after study participation~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Concurrent steroids for the management of symptoms related to lymphoma allowed~Radiotherapy~* No concurrent palliative radiotherapy~Surgery~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive Combination Chemo & Immunotherapy (Type: EXPERIMENTAL): Induction Cycles 1-3: Methotrexate 8gm/m\^2 days 1 \& 15; Leucovorin 100 mg/m\^2 days 2 \& 16; Rituximab 375 mg/m\^2 days 3, 10, 17 \& 24 of cycle 1, days 3 \& 10 of cycle 2; Temozolomide 150 mg/m\^2/day PO days 7-11~Induction Cycle 4: Temozolomide 150 mg/m\^2/day PO days 7-11; Methotrexate 8gm/m\^2 day 15; Leucovorin 100 mg/m\^2 day 16~Consolidation Cycle 5: Methotrexate 8gm/m\^2 days 1; Leucovorin 100 mg/m\^2 days 2; Temozolomide 150 mg/m\^2/day PO days 7-11~Consolidation Cycle 6: Cytarabine 2 g/m\^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m\^2/day starting day 14 until ANC recovers (\>= 500 for 2 consecutive days or \>= 1500 for one day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis chronic obstructive pulmonary disease~* Relatively stable airway obstruction with post FEV1 \>=30 and \< 80% predicted normal and post FEV1/ FVC \< 70%~* Male or female patients, 40 years of age or more~* Smoking history more than 10 pack years~Exclusion criteria:~* Significant diseases other than COPD~* History of asthma~* COPD exacerbation in previous 3 months~* Completion of pulmonary rehabilitation program within previous 6 weeks or current participation in pulmonary rehabilitation program.~* Pregnant or nursing women~* Patients unable to comply with pulmonary medication restrictions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium + olodaterol low dose (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium + olodaterol high dose (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- placebo (Type: PLACEBO_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients~* At least 5 years of age~* A clinical diagnosis of early M. ulcerans disease including:~  * Nodules~ * Plaques and small ulcers with or without oedema and less than or equal to 10cm in maximum diameter~ * Disease duration no longer than six months~ * DRB-PCR positive for M. ulcerans~Exclusion Criteria:~* Treatment with macrolide or quinolone antibiotics, or antituberculous medication, or immunomodulatory drugs including corticosteroids within the previous one month.~* Current treatment with any drugs likely to interact with the study medication, e.g, anticoagulants, cyclosporin, phenytoin, oral contraceptive, and phenobarbitone.~* History of hypersensitivity to rifampicin, streptomycin and or clarithromycin.~* History or having current clinical signs of ascites, jaundice, partial or complete deafness, myasthenia gravis, renal dysfunction (known or suspected), diabetes mellitus, and immune compromise; or evidence for past or present tuberculosis.~* Pregnancy~* Inability to take oral medication or having gastrointestinal disease likely to interfere with drug absorption.~* Excessive alcohol intake.~* Any situation or condition which may compromise ability to comply with the trial procedures.~* Lack of willingness to give informed consent (and/or assent by parent/legal representative).

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SR4/CR4 (Type: EXPERIMENTAL): after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
- SR8 (Type: ACTIVE_COMPARATOR): standard treatment consisting of 8 weeks of streptomycin and rifampicin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perianal Nerval Block in Proctological Interventions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with surgical indication for hemorrhoids, fistula-in-ano or anal fissures.~* Age of 18 or above~Exclusion Criteria:~* age under 18.~* Patients unable to understand an informed consent.~* Emergency operations~* Pregnant women.~* Patients with acute perianal infection.~* Patients allergic to any component of the local anesthetic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 40 mL Saline 0.9%
- Ropivacain (Type: ACTIVE_COMPARATOR): 40 mL Ropivacain 0.5%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age \>=18 patients who complained of dizziness~* Orthostatic hypotension after 3-minute standing (systolic blood pressure drop \>=20 or diastolic blood pressure drop \>=10~Exclusion Criteria:~* Drug-induced hypotension, if necessary, evaluate patient after discontinuing the causative drug for one month~* Heart failure or Chronic renal failure~* Patients who cannot or do not want to write questionaires.~* Poor drug compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Midodrine (Type: EXPERIMENTAL): Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
- Pyridostigmine (Type: EXPERIMENTAL): Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
- Midodrine + Pyridostigmine (Type: EXPERIMENTAL): Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Male or female subjects 12 years of age or older~* Documented history of season allergic rhinitis to mountain cedar pollen~* General good health~* Other criteria apply~Exclusion Criteria:~* History of physical findings of nasal pathology (within 60 days prior to screening visit)~* Participation in any investigational drug study 30 days preceding screening visit~* History of respiratory infection/disorder with 14 days preceding screening visit~* Use of any prohibited concomitant medications~* Other criteria apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BDP HFA 320 µg/day (Type: EXPERIMENTAL): During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
- Placebo (Type: PLACEBO_COMPARATOR): During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of HR+, HER2- metastatic breast cancer (mBC).~* Have all of the following:~  * Recurrent, locally advanced, unresectable or mBC with disease progression following anti-estrogen therapy.~ * Prior treatment with chemotherapy for locally advanced or metastatic disease.~ * No prior treatment with cyclin-dependent kinases (CDK) 4 and 6 inhibitor.~* Have Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1.~* Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.~* Have adequate organ function.~* Women of child-bearing potential must have a negative pregnancy test.~* Are able to swallow tablets/capsules.~Exclusion Criteria:~* Are currently receiving treatment in a clinical study involving an investigational product.~* Have a serious concomitant systemic disorder.~* Have symptomatic central nervous system (CNS) malignancy or metastasis.~* Have a symptomatic Human Immunodeficiency Virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.~* Have a personal history of syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.~* Have a history of any other cancer.~* Had major surgery within 14 days prior to randomization.~* Are breastfeeding.~* Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 200 mg Abemaciclib With a Meal (Type: EXPERIMENTAL): 200 mg abemaciclib given twice a day (BID) orally with a meal.
- 200 mg Abemaciclib Without a Meal (Type: EXPERIMENTAL): 200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
- 200 mg Abemaciclib Without Regard to Food (Type: EXPERIMENTAL): 200 mg abemaciclib given twice a day (BID) orally without regard for food.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria~* Are at least 12 years of age and no older than 65 years~* Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis~* Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to medium doses of ICS (alone or in combination with LABA), used regularly as maintenance asthma therapy~* Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society \[ATS\]/European Respiratory Society \[ERS\] acceptability/repeatability criteria~* Pre-bronchodilator FEV1 of ≥40 to \<90% predicted normal value after withholding SABA for ≥6 hours~* Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1 of ≥15%~* only 2 reversibility testing attempts are allowed~Exclusion Criteria:~* Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)~* Oral corticosteroid use (any dose) within 6 weeks~* Current smokers, former smokers with \>10 pack-years history, or former smokers who stopped smoking \<6 months (including all forms of tobacco, e-cigarettes \[vaping\], and marijuana)~* Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)~* Historical or current evidence of a clinically significant disease~* Cancer not in complete remission for at least 5 years~* Hospitalized for psychiatric disorder or attempted suicide within 1 year~* Unable to abstain from protocol-defined prohibited medications during the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- • AS MDI 90 µg (Type: EXPERIMENTAL): (2 actuations of 45 µg/actuation)
- • AS MDI 180 µg (Type: EXPERIMENTAL): (2 actuations of 90 µg/actuation)
- • Placebo MDI (Type: PLACEBO_COMPARATOR): (2 actuations)
- • Proventil 90 µg (Type: ACTIVE_COMPARATOR): (1 actuation of 90 µg/actuation)
- • Proventil 180 µg (Type: ACTIVE_COMPARATOR): (2 actuations of 90 µg/actuation)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced levodopa-responsive Parkinson's disease, with at least, 2 hours off time or 2 hours of dyskinesia based on clinician's/investigator's medical judgment~* Patients with advanced Parkinson's disease with severe motor fluctuations and dyskinesia when combination of conventional PD treatments was unable to satisfactory control symptoms.~* Patients with advanced Parkinson's disease who meet the criteria for use of Levodopa/Carbidopa Intestinal Gel (LCIG) established in the summary of product characteristics, Spanish Neurology Society (SEN) guidelines, local/regional directories (CCAA) or site's protocols for use of LCIG in common clinical practice.~* The decision to treat with LCIG is made by the physician prior to any decision to approach the patient to participate in this study.~* Patients with a cognitive level enough to complete the questionnaires, confirmed by a Mini-mental state examination (MMSE) score of at least 26 points, according to the recommendation of the Movement Disorder Society (MDS) task force on dementia in Parkinson's Disease (PD)~Exclusion Criteria:~* LCIG's contraindications included in the Summary of Product Characteristics (product label)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- All Participants (Type: None): Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* On a stable dose of metformin as defined by the protocol~* Body mass index (BMI) in the range 22-45~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy or lactation~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular complications~* Laboratory value abnormalities as defined by the protocol~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Vascular Access in Pediatric Intensive Care Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to the pediatric intensive care unit (PICU) who require vascular access.~Exclusion Criteria:~* Age greater than 18 years.~* Any vascular catheter placed outside of the pediatric intensive care unit at Egleston.~* Any vascular catheter placed by a physician other than a member of the pediatric critical care team.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Landmark (Type: None): Procedure/Surgery: Use of landmarks for central line placement
- Ultrasound guided (Type: None): Procedure/Surgery: Use of ultrasound for central line placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete